Sun Pharmaceutical Industries' subsidiary has received US FDA approval for ANDA to market a generic version of GlaxoSmithKline's Wellbutrin SR extended release tablets. It includes three strengths viz., 100 mg, 150 mg and 200 mg. These strengths of generic Bupropion Hydrochloride extended release tablets have a combined annual sale of approximately US$ 300 million in the US and are indicated for the treatment of major depressive disorder.

In India, Sun Pharma is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopaedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.